Home>eczema

eczema

The New York Stock Exchange welcomed Johnson & Johnson to ring the Opening Bell on Dec. 5, 2023, as part of the company's celebration of the 80th anniversary of its "Our Credo." J&J Chairman and CEO Joaquin Duato, as well as several J&J employees, joined Lynn Martin, NYSE president, for the honor.
Jun 24, 2024

Johnson & Johnson completes $850M Proteologix acquisition

As part of the all-cash agreement, J&J assumes ownership of a collection of bispecific meds in development for moderate to severe atopic dermatitis.

On Sept. 14, 2023, Johnson & Johnson unveiled a new brand and visual identity.
May 30, 2024

J&J to acquire experimental eczema drug for $1.25B

The all-cash deal is the second the New Brunswick-based company announced this month for a treatment focused on the skin condition.

On Sept. 14, 2023, Johnson & Johnson unveiled a new brand and visual identity. - JOHNSON & JOHNSON
May 20, 2024

Johnson & Johnson plans $850M Proteologix acquisition

The play for the California biotech will expand the company's dermatology portfolio.

Latest Headlines

NJBIZ Conversations

Hackensack Meridian Health President and COO Mark Sparta speaks with NJBIZ Editor Jeff Kanige on May 14, 2026.

NJBIZ Conversations | SPECIAL EDITION: Hackensack Meridian Health[...]

Hackensack Meridian Health COO Mark Sparta discusses the health system's new facility in MetroPark and th[...]

Events

2026 Best Places to Work in NJ

NJBIZ unveils 2026 Best Places to Work honorees (updated)

8/7/2026
Leading Women in Business

Meet the 2026 NJBIZ Leading Women in Business (updated)

30/6/2026
2026 Health Care Heroes

Pic Page: 2026 NJBIZ Health Care Heroes

29/6/2026
NJBIZ Board Leadership Awards

NJBIZ unveils inaugural Board Leadership Award honorees (updated)

22/6/2026
2026 NJBIZ Leaders in Real Estate, Construction and Design and Top Projects

Pic Page: 2026 NJBIZ Leaders in Real Estate, Construction and Design

15/6/2026